Sofosbuvir and daclatasvir in the treatment of chronic hepatitis c virus infection at benghazi medical center: Our experience

Ahmed Elhaddad; Ahmed Elhassi; Ghada M Hadiia; Samira Taher; Zineb Badr

doi:10.4103/LJMS.LJMS_61_19

Users Online: 285

ORIGINAL ARTICLE

Year : 2019 \| Volume : 3 \| Issue : 4 \| Page : 119-124

Sofosbuvir and daclatasvir in the treatment of chronic hepatitis c virus infection at benghazi medical center: Our experience Ahmed Elhaddad¹, Ahmed Elhassi¹, Ghada M Hadiia², Samira Taher², Zineb Badr³ ¹ Department of Medicine, Infectious Disease Unit, Benghazi Medical Centre; Department of Medicine, Faculty of Medicine, University of Benghazi, Benghazi, Libya ² Department of Medicine, Infectious Disease Unit, Benghazi Medical Centre; Department of Pharmaceutical, Faculty of Pharmacy, University of Benghazi, Benghazi, Libya ³ Department of Medicine, Infectious Disease Unit, Benghazi Medical Centre, University of Benghazi, Benghazi, Libya Correspondence Address: Dr. Ahmed Elhaddad Infectious Disease Unit, Benghazi Medical Center, Faculty of Medicine, University of Benghazi, Benghazi Libya Source of Support: None, Conflict of Interest: None DOI: 10.4103/LJMS.LJMS_61_19

Background: The treatment of hepatitis C virus (HCV) has changed dramatically with the rapid advent of numerous new antiviral agents, including direct-acting antivirals which become the standard of care for HCV infection. Our aim was to investigate the safety and efficacy of combined sofosbuvir (SOF)/daclatasvir (DCV) for HCV in our patients. Patients and Methods: The cohort comprises 157 HCV-infected patients followed from October 2016 to May 2018. The inclusion criteria were treatment experienced or naïve and 18 years or older. Cirrhotic patients included were Child-Turcotte-Pugh A (CTP-A) whereas CTP-B-C patients were excluded. All patients had been treated with SOF/DCV 400/60 mg with or without ribavirin. The primary endpoint was sustained virological response at week 12 (SVR12) and significant adverse events. Results: A total of 157 patients were enrolled in the study with a mean age of 47.74 ± 18.2 years including 48.2% males. Ninety percent of patients were Libyan. One hundred and fifteen (72.9%) patients were treatment naïve. Fifty-eight (36.9%) patients were cirrhotic. The adverse effects of the drug were reported in 25/157 (15.9%); the most commonly reported side effects were gastrointestinal upset and dizziness, whereas hepatic decompensation occurred in five patients and all were cirrhotic and none required drug cessation. Undetectable viremia at the end of treatment was observed in 156 patients (99.3%), and one patient had been labeled as nonresponder. Undetectable viremia 12 weeks after the end of treatment was achieved in 155 patients (98.8%), and only one relapsed. Conclusion: SOF and DCV are safe and efficacious with an SVR12 of about 99.0% among our cohorts. The next step is to improve screening and access to these therapies for eradication of hepatitis C infection from the world and Libya as well in the near future.



[FULL TEXT] [PDF]*

Table of Contents

Similar in PUBMED

Search Pubmed for

Search in Google Scholar for

Related articles

Citation Manager

Access Statistics

Reader Comments

Email Alert *

Add to My List *

* Requires registration (Free)

Article Access Statistics

Viewed	3238

Printed	146

Emailed	0

PDF Downloaded	238

Comments	[Add]